ITI, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$92.1M
Doctors Paid
36,685
Transactions
269,996
2023 Total
$28.4M
Payment Breakdown by Category
Research$69.6M (75.5%)
Food & Beverage$5.9M (6.4%)
Travel$1.4M (1.5%)
Consulting$511,319 (0.6%)
Royalty/License$28,200 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $69.6M | 3,934 | 75.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.3M | 6,527 | 15.6% |
| Food and Beverage | $5.9M | 243,582 | 6.4% |
| Travel and Lodging | $1.4M | 5,275 | 1.5% |
| Consulting Fee | $511,319 | 215 | 0.6% |
| Education | $403,784 | 10,455 | 0.4% |
| Royalty or License | $28,200 | 2 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $9,050 | 6 | 0.0% |
Payments by Type
Research
$69.6M
3,934 transactions
General
$22.5M
266,062 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF LUMATEPERONE FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA | $32.5M | 0 | 687 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | $5.8M | 0 | 800 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients with Schizophrenia | $3.7M | 0 | 68 |
| AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | $2.4M | 0 | 294 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder | $2.2M | 0 | 197 |
| An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia | $2.0M | 0 | 763 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ITI-333 IN NORMAL HEALTHY VOLUNTEERS | $1.6M | 0 | 30 |
| AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER | $1.5M | 0 | 212 |
| AN OPEN-LABEL MULTIPLE ORAL DOSE STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LUMATEPERONE IN PEDIATRIC PATIENTS, AGES 10 TO 17 YEARS, DIAGNOSED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION) | $1.3M | 0 | 46 |
| A PHASE 1, OPEN-LABEL, SINGLE SEQUENCE STUDY TO EVALUATE THE EFFECTS OF PHENYTOIN, A CYP3A4 INDUCER, ON THE PHARMACOKINETICS OF ITI-1284 IN HEALTHY SUBJECTS | $1.2M | 0 | 4 |
| AN OPEN-LABEL MULTIPLE DOSE STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF LUMATEPERONE IN PATIENTS, AGES 13 TO 17 YEARS, DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER | $1.1M | 0 | 57 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCNEDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ITI-333 IN HEALTHY SUBJECTS | $1.0M | 0 | 14 |
| A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE MASS BALANCE, METABOLISM, EXCRETION AND PHARMACOKINETICS OF A SINGLE ORAL DOSE OF [14C]-ITI-1284 IN HEALTHY MALE SUBJECTS | $947,221 | 0 | 5 |
| AN OPEN-LABEL STUDY TO DETERMINE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SINGLE ASCENDING DOSES OF A SUBCUTANEOUS INJECTION OF LUMATEPERONE LONG-ACTING INJECTABLE FORMULATION IN PATIENTS WITH SCHIZOPHRENIA | $928,394 | 0 | 28 |
| AN OPEN-LABEL, ASCENDING DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF LUMATEPERONE IN HEALTHY JAPANESE AND HEALTHY CAUCASIAN SUBJECTS | $854,784 | 0 | 31 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ITI-1020 IN HEALTHY SUBJECTS | $807,572 | 0 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ESCALATING DOSES OF ITI-333 IN HEALTHY SUBJECTS | $774,526 | 0 | 16 |
| ITI-007-403 | $708,517 | 0 | 111 |
| AN OPEN-LABEL, SINGLE SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF LENRISPODUN IN HEALTHY SUBJECTS | $633,163 | 0 | 13 |
| A PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF ITI-214 AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH MOTOR FLUCTUATIONS DUE TO PARKINSON'S DISEASE | $611,150 | 0 | 181 |
| A PHASE 1, RANDOMIZED, CROSS-OVER STUDY TO EVALUATE THE EFFECT OF TIMING OF WATER INTAKE ON THE PHARMACOKINETICS OF ITI-1284 FOLLOWING ADMINISTRATION OF A SINGLE 20 MG SUBLINGUAL TABLET TO HEALTHY SUBJECTS | $588,182 | 0 | 11 |
| A PHASE 1, OPEN-LABEL, SINGLE SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF DILTIAZEM, A MODERATE CYP3A4 INHIBITOR, ON THE PHARMACOKINETICS OF ITI-1284 IN HEALTHY SUBJECTS | $574,981 | 0 | 4 |
| A PHASE 1, OPEN-LABEL, RANDOMIZED, CROSS-OVER STUDY TO EVALUATE THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF LENRISPODUN FOLLOWING ADMINISTRATION OF A SINGLE ORAL TABLET IN HEALTHY SUBJECTS | $543,897 | 0 | 5 |
| A PHASE 1, CROSS-OVER STUDY TO ASSESS THE BIOAVAILABILITY OF 10 MG AND 20 MG ITI-1284 TABLETS ADMINISTERED SUBLINGUALLY AND A 20 MG ITI-1284 TABLET ADMINISTERED ORALLY TO HEALTHY SUBJECTS | $540,970 | 0 | 6 |
| A PHASE 1, LACTATION STUDY IN HEALTHY LACTATING WOMEN RECEIVING A SINGLE DOSE OF LUMATEPERONE | $484,623 | 0 | 21 |
| A Phase 1 Study to Evaluate the Effects of Probenecid, a Non-Specific Inhibitor of Uridine 5'-Diphospho-Glucuronosyltransferases (UGT), on the | $392,586 | 0 | 6 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) | $387,202 | 0 | 130 |
| A PHASE 1, RANDOMIZED, PARALLEL DESIGN STUDY TO EVALUATE THE BIOAVAILABILITY OF TWO DIFFERENT BATCHES OF LENRISPODUN 30 MG TABLET IN HEALTHY SUBJECTS | $353,395 | 0 | 10 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE MONOTHERAPY IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR BIPOLAR II DISORDER (BIPOLAR DEPRESSION) OR MAJOR DEPRESSIVE DISORDER | $323,891 | 0 | 67 |
| AN OPEN-LABEL, POSITRON EMISSION TOMOGRAPHY (PET) STUDY TO EVALUATE BRAIN RECEPTOR, OCCUPANCY, SAFETY, TOLERABILITY AND PHARMACOKINETICS AFTER SINGLE ORAL DOSES OF ITI-333 IN HEALTHY SUBJECTS | $320,737 | 0 | 9 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Andrew Cutler, Md, MD | Psychiatry | Lakewood Ranch, FL | $450,434 | $0 |
| Rakesh Jain, Md, MD | Psychiatry | Lake Jackson, TX | $415,450 | $0 |
| Dr. Mark Reynolds, Md, MD | Psychiatry | Durham, NC | $369,326 | $0 |
| Niku Singh, Md, MD | Psychiatry | Falls Church, VA | $339,356 | $0 |
| Dr. Maxie Gordon, Md, MD | Psychiatry | Clinton, MS | $322,131 | $0 |
| Richard Petty, M.d, M.D | Psychiatry | Loganville, GA | $301,369 | $0 |
| Dr. Donald Ammerman, M.d, M.D | Psychiatry | Danbury, CT | $296,300 | $0 |
| Dr. Charles Tuan-Tu Nguyen, Md, MD | Psychiatry | Irvine, CA | $290,197 | $0 |
| Dr. David Scheiderer, M.d, M.D | Psychiatry | Roanoke, VA | $287,173 | $0 |
| Gregory Mattingly, M.d, M.D | Psychiatry | Saint Charles, MO | $286,481 | $0 |
| Brian Bonfardin, Md, MD | Psychiatry | Johnson City, TN | $284,093 | $0 |
| Dr. Arvinder Pal Walia, M.d, M.D | Psychiatry | Austin, TX | $275,411 | $0 |
| Robert Nelson, M.d, M.D | Professional | Wyomissing, PA | $270,836 | $0 |
| Dr. John Miller, M.d, M.D | Psychiatry | Exeter, NH | $260,550 | $0 |
| Unknown Provider | — | — | $247,289 | $0 |
| Mr. Roueen Rafeyan, M.d, M.D | Addiction Medicine | Chicago, IL | $246,811 | $0 |
| Henry Nasrallah, Md, MD | Psychiatry | Cincinnati, OH | $246,719 | $0 |
| Fred Romeo, Md, MD | Psychiatry | Columbus, OH | $240,993 | $0 |
| John Fenley, Md, MD | Psychiatry | Johnson City, TN | $238,985 | $0 |
| Dr. Sanjay Gupta, Md, MD | Psychiatry | Cheektowaga, NY | $226,122 | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $225,164 | $0 |
| Dr. Gustavo Alva, M.d, M.D | Psychiatry | Orange, CA | $220,692 | $0 |
| Dr. Manoj Waikar, M.d, M.D | Psychiatry | Los Gatos, CA | $218,427 | $0 |
| Dr. Mohd Malik, M.d, M.D | Psychiatry | Saint Louis, MO | $213,817 | $0 |
| Dr. Jonathan Meyer, M.d, M.D | Psychiatry | San Diego, CA | $211,977 | $0 |
About ITI, Inc.
ITI, Inc. has made $92.1M in payments to 36,685 healthcare providers, recorded across 269,996 transactions in the CMS Open Payments database. In 2023, the company paid $28.4M. The top product by payment volume is CAPLYTA ($81.1M).
Payments were distributed across 236 medical specialties. The top specialty by payment amount is Psychiatry ($15.0M to 6,608 doctors).
Payment categories include: Food & Beverage ($5.9M), Consulting ($511,319), Research ($69.6M), Travel & Lodging ($1.4M), Royalties ($28,200).
ITI, Inc. is associated with 1 products in the CMS Open Payments database.